Pluri's 10-K Confirms Going Concern Doubt and EIB Loan Sale Approval
PLUR is trading near its 52-week low of $1.24 (0.8% above the low).
Summary
Pluri's 10-K confirms going concern doubt, less than three months of cash runway, and EIB approval to sell the matured €20 million loan to a third party, potentially converting it to equity.
Key Events · Earnings and Guidance · PLUR
-
Going Concern Opinion
Auditor Kesselman & Kesselman included a going concern explanatory paragraph. The €20 million EIB loan matured June 1, 2026, with no definitive agreement to extend, refinance, or restructure it. The loan can be called for immediate repayment.
-
Cash Runway Under Three Months
Management estimates sufficient resources for less than three months from the financial statement issuance date (September 10, 2026). Cash balances totaled $8.85 million as of June 30, 2026.
-
EIB Loan Sale Approved
On August 17, 2026, the EIB committee approved a proposed sale of the loan to a third-party purchaser who may be a related party. If completed, the company intends to seek conversion of all or a portion of the outstanding loan into equity.
-
Nasdaq Delisting Risk
The company received a Nasdaq deficiency letter on July 7, 2026, for failing the $35 million MVLS requirement. It has until January 4, 2027, to regain compliance.
Analysis · PLUR · Life Sciences
Pluri's annual report confirms the auditor's going concern opinion: the €20 million EIB loan matured June 1, 2026, and no definitive agreement has been reached to extend or restructure it. The company has less than three months of cash runway. The EIB has approved a proposed sale of the loan to a third-party purchaser who may be a related party, with potential conversion into equity. This is a critical liquidity event for a company already facing Nasdaq delisting.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 553 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLUR was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $1.24 to $5.17. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.